Vanda surges after FDA approval for antipsychotic drug
ReutersFeb 20, 2026 11:35 PM
Shares of drugmaker Vanda Pharmaceuticals' VNDA.O rise 34.7% to $7.77 in extended trading
U.S. FDA approves co's antipsychotic drug Bysanti
Drug aimed at treating mental health conditions schizophrenia and acute bipolar I disorder
Approval comes with FDA's most serious warning of increased risk of death in elderly patients with dementia-related psychosis
In 2025, stock rose 84.1%
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Related Articles
Will Micron Be the 2026 AI Winner as the Memory Supercycle Begins?
Recently, Micron has focused on premium areas such as High-Bandwidth Memory that plays alongside accelerators to feed AI models, and adding capacity with an eye on pricing discipline.TradingKey
2 hours ago
Stock Market Crash 2026: What Fed Signals and Economic Data Mean for Investors
TradingKey - The possibility of a stock market crash occurring in 2026 is becoming increasingly likely as investor sentiment continues to decline.TradingKey
Thu, Feb 19
Digital Asset Rotation: Navigating Market Volatility With the Best Cheap Cryptos for 2026
Navigate the 2026 crypto rotation: Analyze the best cheap cryptos like Solana, Chainlink, and XRP amid Bitcoin’s volatility. Discover top picks for utility and long-term gains.TradingKey
Wed, Feb 18
